Immune Evasion of Autophagy in Gamma-Herpesviruses infection
Immune Evasion of Autophagy in Gamma-Herpesviruses infection
批准号:
7708651
负责人:
Chengyu Liang
金额:
$24.45万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-15 至 2011-05-31
关键词:
AcuteAffectAffinityApoptosisApoptoticAutophagocytosisAutophagosomeBindingBiochemicalBiologicalCell physiologyCellsChronicComplexEatingFamilyGenesGeneticGenomeHerpesviridaeHerpesviridae InfectionsHomologous GeneHost Defense MechanismHumanHuman Herpesvirus 4Human Herpesvirus 8ImmuneImmunityIn VitroInfectionLifeLipidsLysosomesMaintenanceMalignant NeoplasmsMediatingMethodsMolecularMusMutationNutrientPathogenesisPathway interactionsPhasePhosphotransferasesPlayProteinsRecyclingRoleSaimiriine Herpesvirus 2StarvationStressSystemTestingTherapeuticTumor Suppressor ProteinsVesicleViralVirulenceVirulence FactorsVirusVirus Diseasesassaultbasegammaherpesvirusin vivoin vivo Modelinhibition of autophagyinsightkillingslytic replicationmutantnovelpathogenpro-apoptotic proteinpublic health relevanceresponsetherapeutic development
中文摘要
描述(由申请人提供):3-疱疹病毒(3-HVs)已经发展出一种独特的与宿主相互作用的模式,以建立终身持续感染,这通常与各种恶性肿瘤的发病有关。参与3- hv持久性和致癌性的一个关键毒力因子是所有3- hv编码的Bcl-2蛋白(称为vBcl-2)的病毒同源物。除了具有良好的抗凋亡活性外,我们的初步研究已经确定,3-HV家族的vBcl-2通过直接靶向关键的自噬效应蛋白Beclin1,有效地抑制了抗病毒自噬途径(“自噬”,依赖溶酶体的降解和细胞内成分在应激反应中的再循环)。此外,与宿主对应物相比,vBcl-2具有增强的抗自噬活性。基于这些发现,我们假设vcl -2对自噬的抑制是3- hv逃避宿主免疫并赋予持续感染和发病机制的新机制。为了验证这一假设,我们将主要关注3HV68的vBcl-2,使用成熟的体外和体内系统。3HV68与EBV和KSHV具有广泛的基因同源性和生物学相似性。3HV68感染小鼠为表征3hv慢性感染提供了一种遗传上可处理的体内模型。值得注意的是,失去vBcl-2并不影响3HV68的裂解复制。相反,它严重损害了3HV68在小鼠体内建立慢性感染的能力。在第一个目标中,我们将剖析vBcl-2拮抗beclin1依赖性自噬的分子机制。我们已经成功地鉴定了区分vbcl -2介导的自噬抑制和vbcl -2介导的细胞凋亡拮抗的特异性突变。在第二个目标中,我们将研究vcl -2介导的抗自噬在体内病毒毒力中的具体作用。本研究将揭示vBcl-2在3hv感染中的作用,并建立自噬作为宿主抵抗病毒感染的基本防御机制。公共卫生相关性:自噬在宿主抗病毒防御中越来越被认为是必不可少的,但其在3-疱疹病毒感染中的作用仍然很大程度上未知。本研究旨在了解vbcl -2介导的自噬抑制的分子机制,及其在3-疱疹病毒持续感染和/或发病机制中的作用。从这项研究中获得的见解将建立自噬在病毒毒力控制中的直接作用,并提出急需的抗病毒治疗策略。
英文摘要
DESCRIPTION (provided by applicant): 3-Herpesviruses (3-HVs) have developed a unique mode of interaction with their hosts to establish a life-long persistent infection, which frequently associates with the onset of various malignancies. One critical virulence factor involved in 3-HVs persistence and oncogenicity are the viral homologs of the Bcl-2 protein (referred to as vBcl-2) encoded by all 3-HVs. Alongside its well-characterized anti-apoptotic activity, our preliminary studies have established that the vBcl-2 of the 3-HV family effectively suppresses the anti-viral autophagy pathway ('self-eating', lysosome-dependent degradation and recycling of the intracellular components in response to stress), by directly targeting a key autophagy effector protein, Beclin1. Moreover, vBcl-2 has evolved enhanced anti-autophagic activity when compared to the host counterpart. Based on these findings, we hypothesize that the inhibition of autophagy by vBcl-2 constitutes a novel mechanism by which 3- HVs evade host immunity and confer persistent infection and pathogenesis. To test this hypothesis, we will focus primarily on the vBcl-2 of 3HV68 using well-established in vitro and in vivo systems. 3HV68 shares extensive genetic homology and biological similarity with EBV and KSHV. Infection of mice with 3HV68 provides a genetically tractable in vivo model for characterizing the chronic infection of 3HVs. Notably, the loss of vBcl-2 does not affect the lytic replication of 3HV68. Instead, it severely impairs the ability of 3HV68 to establish chronic infection in mice. In the first aim, we will dissect the molecular mechanism by which vBcl-2 antagonizes Beclin1-dependent autophagy. We have successfully identified the specific mutations that distinguish vBcl-2-mediated inhibition of autophagy from vBcl-2-mediated antagonism of apoptosis. In the second aim, we will investigate the specific roles of vBcl-2-mediated anti-autophagy in viral virulence in vivo. Insights gained from this study will reveal a novel paradigm for the roles of vBcl-2 in 3HVs infection, and establish autophagy as a fundamental host defensive mechanism against viral infections. PUBLIC HEALTH RELEVANCE: Autophagy has been increasingly recognized essential in host anti-viral defense, but its role in 3- herpesviruses infection remains largely unknown. The proposed study is targeted to understand the molecular mechanism of vBcl-2-mediated inhibition of autophagy, and its contribution to the persistent infection and/or pathogenesis of 3-herpesviruses. Insights gained from this study will establish a direct role for autophagy in viral virulence control and suggest strategy for much- needed anti-viral therapeutics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
New control of oncogene activation in T-cell leukemia
-
批准号:10609073
-
项目类别:
-
资助金额:$50.42万
-
财政年份:2022
-
负责人:Chengyu Liang
-
依托单位:
New control of oncogene activation in T-cell leukemia
-
批准号:10443113
-
项目类别:
-
资助金额:$54.19万
-
财政年份:2022
-
负责人:Chengyu Liang
-
依托单位:
Molecular Mechanism of UV Protection in Cutaneous Melanoma
-
批准号:10294255
-
项目类别:
-
资助金额:$62.23万
-
财政年份:2020
-
负责人:Chengyu Liang
-
依托单位:
A cancer-derived truncating mutation in disease penetrance and progression of MSI CRC
-
批准号:10264124
-
项目类别:
-
资助金额:$57.74万
-
财政年份:2020
-
负责人:Chengyu Liang
-
依托单位:
Targeting the host NDP kinase to abrogate viral dissemination
-
批准号:10223818
-
项目类别:
-
资助金额:$13.63万
-
财政年份:2020
-
负责人:Chengyu Liang
-
依托单位:
Molecular Mechanism of UV Protection in Cutaneous Melanoma
-
批准号:10542439
-
项目类别:
-
资助金额:$62.23万
-
财政年份:2020
-
负责人:Chengyu Liang
-
依托单位:
A cancer-derived truncating mutation in disease penetrance and progression of MSI CRC
-
批准号:10320079
-
项目类别:
-
资助金额:$56.58万
-
财政年份:2020
-
负责人:Chengyu Liang
-
依托单位:
A cancer-derived truncating mutation in disease penetrance and progression of MSI CRC
-
批准号:10517499
-
项目类别:
-
资助金额:$57.04万
-
财政年份:2020
-
负责人:Chengyu Liang
-
依托单位:
Molecular Mechanism of UV Protection in Cutaneous Melanoma
-
批准号:10318542
-
项目类别:
-
资助金额:$62.23万
-
财政年份:2020
-
负责人:Chengyu Liang
-
依托单位:
A cancer-derived truncating mutation in disease penetrance and progression of MSI CRC
-
批准号:10230378
-
项目类别:
-
资助金额:$43.0万
-
财政年份:2020
-
负责人:Chengyu Liang
-
依托单位:
Molecular Mechanism of UV Protection in Cutaneous Melanoma
-
批准号:10225017
-
项目类别:
-
资助金额:$43.97万
-
财政年份:2020
-
负责人:Chengyu Liang
-
依托单位:
A cancer-derived truncating mutation in disease penetrance and progression of MSI CRC
-
批准号:9885369
-
项目类别:
-
资助金额:$19.05万
-
财政年份:2019
-
负责人:Chengyu Liang
-
依托单位:
A Novel Modulator of Notch in Acute Lymphoblastic Leukemia
-
批准号:8309060
-
项目类别:
-
资助金额:$17.62万
-
财政年份:2011
-
负责人:Chengyu Liang
-
依托单位:
A Novel Modulator of Notch in Acute Lymphoblastic Leukemia
-
批准号:8177140
-
项目类别:
-
资助金额:$20.76万
-
财政年份:2011
-
负责人:Chengyu Liang
-
依托单位:
Novel mechanism for UVRAG in genome stability and tumor suppression
-
批准号:8979682
-
项目类别:
-
资助金额:$35.27万
-
财政年份:2009
-
负责人:Chengyu Liang
-
依托单位:
Immune Evasion of Autophagy in Gamma-Herpesviruses infection
-
批准号:7871367
-
项目类别:
-
资助金额:$20.06万
-
财政年份:2009
-
负责人:Chengyu Liang
-
依托单位:
Role of UVRAG-mediated Autophagy in Tumor Suppression
-
批准号:8115770
-
项目类别:
-
资助金额:$29.35万
-
财政年份:2009
-
负责人:Chengyu Liang
-
依托单位:
Role of UVRAG-mediated Autophagy in Tumor Suppression
-
批准号:8509618
-
项目类别:
-
资助金额:$27.59万
-
财政年份:2009
-
负责人:Chengyu Liang
-
依托单位:
Novel mechanism for UVRAG in genome stability and tumor suppression
-
批准号:10221855
-
项目类别:
-
资助金额:$12.44万
-
财政年份:2009
-
负责人:Chengyu Liang
-
依托单位:
Autophagy-mediated defense against inflammation and cancer
-
批准号:10296149
-
项目类别:
-
资助金额:$41.58万
-
财政年份:2009
-
负责人:Chengyu Liang
-
依托单位:
海外基金